Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Divalproex sodium in migraine prophylaxis: a dose-controlled study

J Klapper1

  • 1Colorado Neurology and Headache Clinic, Denver 80218, USA.

Cephalalgia : an International Journal of Headache
|April 1, 1997
PubMed
Summary

Divalproex sodium (DVPX) effectively reduces migraine frequency as prophylactic monotherapy. The drug is generally well-tolerated, with most adverse events being mild and manageable for migraine patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild.

Cephalalgia : an international journal of headache·2004
Same author

Triptans in the treatment of basilar migraine and migraine with prolonged aura.

Headache·2002
Same author

Oral contraceptives, other methods of contraception, and risk reduction for ovarian cancer.

Epidemiology (Cambridge, Mass.)·2001
Same author

Efficacy of gabapentin in migraine prophylaxis.

Headache·2001
Same author

Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer.

Epidemiology (Cambridge, Mass.)·2000
Same author

Racial differences in ovarian cancer risk.

Journal of the National Medical Association·2000

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Migraine is a common neurological disorder.
  • Prophylactic treatment aims to reduce migraine frequency and severity.

Purpose of the Study:

  • To assess the efficacy and safety of divalproex sodium (DVPX) as a prophylactic monotherapy for migraine patients.

Main Methods:

  • A multicenter, double-blind, placebo-controlled trial.
  • Patients received placebo during a 4-week baseline, then were randomized to DVPX (500, 1000, or 1500 mg daily) or placebo for 12 weeks.
  • Primary endpoint was the reduction in 4-week migraine attack frequency.

Main Results:

  • DVPX significantly reduced migraine attack frequency compared to placebo across all doses (1.7-2.0 attacks vs 0.5 attacks per 4 weeks).

Related Experiment Videos

  • 44-45% of DVPX patients achieved ≥50% reduction in migraine frequency, versus 21% of placebo patients.
  • Adverse events were similar, except for higher rates of nausea, dizziness, and tremor with DVPX, particularly at 1500 mg.

    • Conclusions:

    • Divalproex sodium is an effective prophylactic treatment for migraine.
    • The drug is generally well-tolerated, with an initial recommended dose of 500 mg daily.